Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23757451 | 0.72 | PRMT5 (0.51) | PRMT5KCNH2NOS3NOS1NOS2 | |
| SCHEMBL25522111 | 0.71 | CYP1A2 (0.40) | PRMT5CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13724582 | 0.71 | UHRF1 (0.54) | NOS3NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL29184309 | 0.71 | NOS3 (0.40) | NOS3NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL25521904 | 0.69 | PRMT5 (0.46) | PRMT5KCNH2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6628386 | 0.68 | NOS3 (0.44) | NOS3NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL29952328 | 0.68 | NOS3 (0.44) | NOS3NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL844731 | 0.66 | DYRK1A (0.37) | NQO1 | |
| SCHEMBL29955122 | 0.65 | GRIA1 (0.38) | CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30567636 | 0.64 | MAPT (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885KCNH2 4476/4885NOS3 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.